(CDA Powder), 2-chlorodeoxyadenosine (CDA), is a synthetic nucleoside analog drug used to treat certain blood cancers and multiple sclerosis. It was first synthesized in the 1970s by researchers at the Southern Research Institute in Birmingham, Alabama, United States.
Since this raw powder assumes a significant part in all parts of clinical treatment and can successfully control cell lesions, Cladribine has become a hot-selling item among homegrown manufacturers, vast and small. When confronted with such countless decisions, the nature of the article has turned Xi'an Sonwu into not simply ready to give high-immaculateness crude powder but also the most favorable price.
|
99% |
99.31% |
|
|
100% through 80 mesh |
80 mesh |
|
|
Less than or equal to 0.5% |
0.09% |
|
|
Less than or equal to 2.0% |
0.13% |
|
|
Less than or equal to 15ppm |
4ppm |
|
|
Less than or equal to 0.5ppm |
||
|
Less than or equal to 1ppm |
||
|
Less than or equal to 2ppm |
0.2ppm |
|
|
Less than or equal to 1000cfu/g |
71cfu/g |
|
|
Less than or equal to 100cfu/g |
13cfu/g |
|
Sonwu has nearly 15 years of experience in international trade and possesses a high level of knowledge and technology to ensure proper pharmaceutical raw material quality and compliance with the production process standards.
At the same time, communicate with customers regularly to ensure that the requirements of customers are met and provide customers with industry-related information and technical support. So look for Xi'an Sonwu Biotech Co. Ltd. when buying CDA.
|
50g |
100g |
Xi'an Sonwu cannot only supply high-quality Cladribine Powder But also supply its packaging customization.
1. Customized bottles(size, color, material, style)
2. Customized packaging(vacuum foil packaging, box, drum)
3. Customized label(paint film, matte film, optical mask)
CDA has been approved in several countries for treating relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS). It is available orally, offering convenience and ease of administration to patients. Clinical studies have demonstrated that CDA significantly reduces the frequency of relapses, slows disability progression, and delays the accumulation of lesions in the CNS. It provides an important treatment option for MS patients, particularly those who may not tolerate or respond sufficiently to other disease-modifying therapies.
CDA treats specific blood lesion cells, such as hairy cell leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma, by inhibiting DNA synthesis and inducing apoptosis in rapidly dividing lesion cells. Additionally, it is used to manage multiple sclerosis by modulating the immune system and reducing inflammation in the central nervous system. The use of CDA should be determined by healthcare professionals based on individual patient characteristics and the specific indications for which it is approved.
1. Best Quality
2. OEM Service
3. Good Service
With more than 10-year trade experience, Xi'an Sonwu can help customers solve all kinds of problems and supply professional service before and after sales, making sure customers receive goods smoothly.
E-mail: sales@sonwu.com
Cim npe nrov:
